Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Operating Leases: 2019-2024

Historic Operating Leases for Akebia Therapeutics (AKBA) over the last 6 years, with Dec 2024 value amounting to $3.5 million.

  • Akebia Therapeutics' Operating Leases fell 51.73% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 51.73%. This contributed to the annual value of $3.5 million for FY2024, which is 60.36% down from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Operating Leases is $3.5 million, which was down 60.36% from $8.9 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Operating Leases registered a high of $33.7 million during FY2021, and its lowest value of $3.5 million during FY2024.
  • For the 3-year period, Akebia Therapeutics' Operating Leases averaged around $13.8 million, with its median value being $8.9 million (2023).
  • As far as peak fluctuations go, Akebia Therapeutics' Operating Leases skyrocketed by 36.89% in 2021, and later crashed by 69.11% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Operating Leases (MRY) stood at $24.6 million in 2020, then surged by 36.89% to $33.7 million in 2021, then decreased by 14.07% to $29.0 million in 2022, then tumbled by 69.11% to $8.9 million in 2023, then crashed by 60.36% to $3.5 million in 2024.
  • Its Operating Leases stands at $3.5 million for FY2024, versus $8.9 million for FY2023 and $29.0 million for FY2022.